Xilio Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Xilio Therapeutics has a total shareholder equity of $36.8M and total debt of $3.3M, which brings its debt-to-equity ratio to 9%. Its total assets and total liabilities are $60.9M and $24.1M respectively.
Key information
9.0%
Debt to equity ratio
US$3.32m
Debt
| Interest coverage ratio | n/a |
| Cash | US$44.70m |
| Equity | US$36.83m |
| Total liabilities | US$24.10m |
| Total assets | US$60.93m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: XLO's short term assets ($48.1M) exceed its short term liabilities ($16.0M).
Long Term Liabilities: XLO's short term assets ($48.1M) exceed its long term liabilities ($8.1M).
Debt to Equity History and Analysis
Debt Level: XLO has more cash than its total debt.
Reducing Debt: Insufficient data to determine if XLO's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XLO has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: XLO is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.